Deep Brain Stimulation (DBS) is a medical procedure that involves the implantation of a device, called a neurostimulator, in the brain. The device delivers electrical impulses to specific areas of the brain, which can help to alleviate symptoms of certain neurological disorders, such as Parkinson's disease, dystonia, and essential tremor.

The global market for DBS devices is expected to grow significantly in the coming years, driven by an increasing aging population and a rise in the prevalence of neurological disorders. Additionally, advancements in technology and an increasing number of FDA approvals for DBS devices are also expected to drive market growth.

DBS devices can be divided into two main categories: rechargeable and non-rechargeable. Rechargeable devices are becoming more popular, as they do not require surgery to replace the battery, and they have a longer lifespan. However, they are more expensive than non-rechargeable devices.

The major players in the DBS devices market include Medtronic, Boston Scientific, St. Jude Medical, and Abbott. These companies have a significant presence in the market due to their strong product portfolios and distribution networks.

However, the high cost of DBS devices and the lack of reimbursement policies in certain countries are some of the major challenges faced by the market. Additionally, the surgical procedure associated with the implantation of DBS devices is complex and carries a risk of complications, which may limit its adoption in certain patient populations.

Overall, the DBS devices market is expected to grow at a significant pace in the coming years, driven by an increasing aging population, rising prevalence of neurological disorders, and advancements in technology. However, the high cost of the devices and the lack of reimbursement policies in certain countries may pose a challenge to market growth.